Our gene knockout and pharmacological inhibition studies also confirmed the off-target inhibition of ABCG2 by erlotinib as the mechanism of synergism with SN-38 in SNU5 cells, derived from a gastric adenocarcinoma patient who previously received chemotherapy. Here, ABCG2 is linked to gastric adenocarcinoma.